Fig. 4

ppFEV1 is lower in NE^Hi donors prior to the start of ETI and remains low. (A) Retrospective analysis of lung function was conducted from the medical record of sputum donors. A type III mixed effects model indicated significant difference (indicated on the graph) and Sidak multiple comparison test also showed significant (adjusted p < 0.05) differences of the following time points relative to the year of ETI therapy start: −4, −1, 0, 1, 2, 3. Data are shown as median with interquartile range. The n per group are as follows (NE^Lo followed by NE^Hi): Year − 5, n = 4 and n = 8; Years − 4 and − 3, n = 12 and n = 16; Year − 2, n = 13 and n = 16; Year − 1, n = 13 and n = 15; Year 0, n = 12 and n = 16; Year 1, n = 12 and n = 14; Year 2, n = 12 and n = 15; Year 3, n = 5 and n = 7. (B) Change in ppFEV1 after the year of ETI introduction was tested for up to 3 years following start of therapy. Data are shown as median with interquartile range. No significant differences were observed. The n per group are as follows (NE^Lo followed by NE^Hi): Year 1, n = 11 and n = 14; Year 2, n = 11 and n = 15; Year 3, n = 5 and n = 7.